Erythropoietin for the treatment of anemia associated with hematological malignancy

Hematological Oncology

Volumn 19, Issue 1, 2001, Pages 19-30

  Littlewood, T J ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anemia; Cancer; Erythropoietin

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; ERYTHROPOIESIS; FATIGUE; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HORMONE BLOOD LEVEL; HUMAN; INCIDENCE; IRON DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASIA; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 0035064082     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.663     Document Type: Review

References (38)

1. Regulation of the erythropoietin gene
2. Use of recombinant erythropoietin outside the setting of uraemia
3. Control of red cell production: The roles of programmed cell death (apoptosis) and erythropoietin
4. Recombinant human erythropoietin and the anaemia of cancer
5. Decreased erythropoietin response in patients with the anemia of cancer
6. A new staging system for multiple myeloma based on the number of S-phase plasma cells
7. Multiple myeloma: Review of 869 cases
8. Anemia associated with non-platinum chemotherapy (CT) for Hodgkins lymphoma (HL) or non-Hodgkins lymphoma (NHL)
9. Patient, caregiver and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
10. Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
11. Erythropoietin treatment of anemia associated with multiple myeloma
12. Recombinant human erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomised multicentre study
13. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of the predictors of response
14. Epoetin alfa for the treatment of the anemia of multiple myeloma
15. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
16. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (epo)
17. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
18. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
19. Identifying haemoglobin level for optimal quality of life: Results of an incremental analysis
20. Efficacy and quality of life outcomes of epoetin alpha in a double blind placebo controlled multicentre study of cancer patients receiving non-platinum containing chemotherapy
21. Possible relationship of haemoglobin levels with survival in anemic cancer patients receiving chemotherapy
22. Once-weekly dosing of Epoetin alpha is similar to three-times-weekly dosing in increasing haemoglobin and quality of life
23. Prediction of response to erythropoietin treatment in chronic anaemia of cancer
24. Detection of functional iron deficiency during erythropoietin treatment: A new approach
25. A randomised double-blind placebo controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes
26. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes
27. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies
28. Treatment of the anaemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor in combination with erythropoietin
29. Treatment of anaemia in myelodysplastic syndromes with granulocyte colony stimulating factor plus erythropoietin: Results from a randomized phase II study and long term follow up of 71 patients
30. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin
31. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposals for a predictive model
32. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients
33. Impaired erythropoietin response to anaemia after bone marrow transplantation
34. A controlled trial of recombinant human erythropoietin after bone marrow transplantation
35. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: Results of a randomised, double-blind study with high-dose erythropoietin
36. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors
37. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilisation
38. The annual cost of blood transfusions in the United Kingdom